LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Elenco Azioni・Cytokinetics Inc

Cytokinetics Inc

Chiusa

SettoreSettore sanitario

74.53 -2.89

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

74.04

Massimo

78.45

Metriche Chiave
By Trading Economics
Entrata	123M -183M
Vendite	16M 18M
Margine di Profitto	-1,030.87
Dipendenti	673
EBITDA	97M -180M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+29.87% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-140M 8.2B
Apertura precedente	77.42
Chiusura precedente	74.53

Notizie sul Sentiment di mercato

By Acuity

40%

60%

134 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

32.3 / 40.43 Supporto e resistenza

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 mag 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mag 2026, 23:46 UTC

Discorsi di Mercato

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mag 2026, 23:33 UTC

Discorsi di Mercato

Gold Rises on Possible Position Adjustments -- Market Talk

11 mag 2026, 22:37 UTC

Discorsi di Mercato

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mag 2026, 22:32 UTC

Utili

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mag 2026, 22:02 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mag 2026, 21:49 UTC

Utili

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mag 2026, 21:42 UTC

Discorsi di Mercato

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mag 2026, 21:23 UTC

Acquisizioni, Fusioni, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mag 2026, 21:12 UTC

Utili

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mag 2026, 21:12 UTC

Utili

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

11 mag 2026, 20:44 UTC

Utili

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mag 2026, 20:43 UTC

Utili

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Rev $136.4M >CLSK

11 mag 2026, 20:30 UTC

Utili

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Cont Ops EPS $2.24 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Rev $1.6B >STE

11 mag 2026, 20:30 UTC

Utili

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Adj EPS $2.83 >STE

11 mag 2026, 20:22 UTC

Azioni calde

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mag 2026, 19:37 UTC

Utili

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mag 2026, 19:32 UTC

Discorsi di Mercato

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

29.87% in crescita

Previsioni per 12 mesi

Media 99.88 USD 29.87%

Alto 140 USD

Basso 67 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Cytokinetics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

32.3 / 40.43Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

134 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.